当前位置： SCI文献检索 > CURRENT MEDICAL RESEARCH AND OPINION期刊下所有文献 > Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Abstract：

OBJECTIVES:Docetaxel and paclitaxel show significant clinical activity in metastatic breast cancer (MBC) and have been approved for MBC by the U.S. Food and Drug Administration, but it is still unclear whether a paclitaxel-based regimen improves outcomes over a docetaxel-based regimen in patients with MBC. We therefore performed a meta-analysis of randomized controlled trials to compare the safety and efficacy of these two regimens in MBC. METHODS:We systematically searched for randomized controlled trials that comparing paclitaxel-based with docetaxel-based regimens in patients with MBC in PubMed (up to January 2012), Embase (1980 to January 2012), and the Cochrane databases (up to January 2012). Abstracts presented at conferences (up to January 2011) were also searched. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed by Stata version 12.0 software (Stata Corporation, College Station, TX, USA). RESULTS:Seven eligible trials involving 1694 patients with MBC were selected. Our results showed that a paclitaxel-based regimen was comparable to a docetaxel-based regimen for MBC patients in terms of OS (HR: 0.87, 95% CI: 0.60-1.27, p = 0.48), PFS (HR: 0.76, 95% CI: 0.58-1.00, p = 0.052), TTP (HR: 1.13, 95% CI: 0.81-1.58, p = 0.46), and ORR (RR: 1.01, 95% CI: 0.88-1.15, p = 0.92), but fewer grade 3 or 4 adverse events including anemia (RR: 0.64, 95% CI: 0.44-0.94, p = 0.023), neutropenia (RR: 0.74, 95% CI: 0.58-0.93, p = 0.011), febrile neutropenia (RR: 0.38, 95% CI: 0.15-0.96, p = 0.041), thrombopenia (RR: 0.62, 95% CI: 0.41-0.96, p = 0.033), mucositis (RR: 0.082, 95% CI: 0.025-0.27, p < 0.001), diarrhea (RR: 0.19, 95% CI: 0.081-0.47, p < 0.001) and fatigue (RR: 0.43, 95% CI: 0.20-0.96, p = 0.039) were observed in the paclitaxel-based regimen. However, limitations of our study needed to be considered when interpreting these results: our study was a meta-analysis of published data, and there was significant heterogeneity among included trials. Potential publication bias might also exist. CONCLUSION:The present systematic review and meta-analysis demonstrates that both taxane-based regimens have comparable efficacy for patients with MBC, and the paclitaxel-based regimen is associated with less toxicity and better tolerability, especially in older patients and when used in weekly regimens.

journal_name

Curr Med Res Opin

journal_title

Current medical research and opinion

authors

Qi WX,Shen Z,Lin F,Sun YJ,Min DL,Tang LN,He AN,Yao Y

doi

10.1185/03007995.2012.756393

subject

Has Abstract

pub_date

2013-02-01 00:00:00

pages

117-25

issue

eissn

0300-7995

issn

1473-4877

journal_volume

pub_type

杂志文章,meta分析,评审

在线工具

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.